2019 Consensus Korean Diagnostic Guidelines to Define Severity Classification and Treatment Refractoriness for Atopic Dermatitis: Objective and Subjective Assessment of Severity

Systemic immunomodulatory treatment is actively recommended in the treatment for moderate to severe atopic dermatitis (AD) patients. However, consensus criteria for the classification of AD severity or treatment refractoriness have not been established yet. To establish consensus criteria on the def...

Full description

Saved in:
Bibliographic Details
Published in:Annals of dermatology 2019, 31(6), , pp.654-661
Main Authors: Kim, Jung Eun, Shin, Min Kyung, Park, Gyeong-Hun, Lee, Un Ha, Lee, Ji Hyun, Han, Tae-Young, Koh, Hyun Chang, Jang, Yong Hyun, Kim, Hye One, Na, Chan Ho, Lew, Bark-Lynn, Ahn, Ji Young, Park, Chang Ook, Seo, Young Joon, Lee, Yang Won, Sohn, Sang Wook, Park, Young Lip
Format: Article
Language:English
Subjects:
Original
피부과학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Systemic immunomodulatory treatment is actively recommended in the treatment for moderate to severe atopic dermatitis (AD) patients. However, consensus criteria for the classification of AD severity or treatment refractoriness have not been established yet. To establish consensus criteria on the definition of severity classification and treatment refractoriness of AD to provide a basis for proper treatment strategy. The Korean Atopic Dermatitis Association (KADA) comprised a task force team to establish a definition of moderate to severe AD. A draft of definition of moderate to severe AD was made on the basis of evidence. The recommendation was confirmed by KADA members through a web-based survey. KADA approved that AD with 16≤eczema area and severity index (EASI)
ISSN:1013-9087
2005-3894
2005-3894
DOI:10.5021/ad.2019.31.6.654